Skip to main content

Orlistat Disease Interactions

There are 4 disease interactions with orlistat.

Major

Orlistat (applies to orlistat) malabsorption

Major Potential Hazard, High plausibility. Applicable conditions: Malabsorption Syndrome, Biliary Obstruction

The use of orlistat is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Orlistat can worsen the malabsorption in these conditions by reversibly inhibiting lipases that are necessary for the hydrolysis of triglycerides into absorbable free fatty acids and monoglycerides. At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.

Moderate

Obesity drugs (applies to orlistat) diabetics

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Type 2

Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight. Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.

Moderate

Orlistat (applies to orlistat) (fat soluble) vitamin deficiency

Moderate Potential Hazard, High plausibility. Applicable conditions: Vitamin A Deficiency, Vitamin D Deficiency, Vitamin K Deficiency

At the recommended therapeutic dosage of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30% and has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. Therapy with orlistat should be administered cautiously in patients with preexisting deficiency of one or more fat-soluble vitamins (A, D, E and K). Ideally, the deficiency should be corrected prior to initiation of therapy. A multivitamin supplement containing fat-soluble vitamins is recommended during therapy, best taken once a day at least 2 hours before or after the administration of orlistat.

Moderate

Orlistat (applies to orlistat) nephrolithiasis

Moderate Potential Hazard, Moderate plausibility.

Following treatment with orlistat, some patients may develop increased levels of urinary oxalate as a result of fat malabsorption. Therapy with orlistat should be administered cautiously in patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.

Switch to professional interaction data

Orlistat drug interactions

There are 145 drug interactions with orlistat.

Orlistat alcohol/food interactions

There is 1 alcohol/food interaction with orlistat.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer